Speaker Profile
M.D., Ph.D., VP, BMS
Biography
Mike Burgess serves as SVP and Head of the Cell Therapy Thematic Research Center at Bristol Myers Squibb (BMS), overseeing discovery and translational research for the company’s cell therapy pipeline. He concurrently leads Translational Medicine & Clinical Pharmacology at BMS, directing the strategy and execution of end-to-end clinical and quantitative pharmacology and the translational and precision medicine strategy for late-stage clinical development across oncology, hematology, immunology, cardiovascular, and neuroscience therapeutic areas. Mike is a board observer for Arsenal Biosciences and Orna Therapeutics. He brings extensive experience from his previous roles at BMS and Celgene Corporation in Early Clinical Development where he advanced numerous clinical-stage programs and strategic partnerships.
Mike joined the industry from the University of California, San Francisco (UCSF) where he remains on volunteer faculty as Assistant Professor caring for patients with hematologic malignancies. Mike completed his undergraduate degree at UC, Berkeley, earned his MD and PhD in molecular biology at UCLA and completed postgraduate training in internal medicine, hematology, and medical oncology at UCSF. Mike lives in San Francisco, CA, with his wife and two children and is based at the Brisbane BMS site.
Session Abstract – PMWC 2027 Silicon Valley
Track Chair:
Ira Mellman, Medici Therapeutics
PMWC Award Ceremony
• Jedd D. Wolchok, Weill Cornell Medicine
• Suzanne Topalian, Johns Hopkins
• Levi Garraway, Roche
Keynote: Future Breakthroughs in Immuno-Oncology: New Targets, Modalities & Combinations
• Levi Garraway, Roche
Checkpoint 2.0 in Practice: PD-1+VEGF Wins, Resistance Salvage & Biomarker Gates
• Chair: Anne Kasmar, Parexel
• Jedd D. Wolchok, Weill Cornell Medicine
• Roy S. Herbst, Yale
• Nathan Fowler, BostonGene
Immunotherapy with Personalized Cancer Vaccines: Who, When, How Fast?
• Chair: Suzanne Topalian, Johns Hopkins
• Tal Zaks, Orbimed
• Lelia Delamarre, Genentech
The Next Era: Neutralizing On-Target, Off-Tumor Effects by Turning Cancer Against Itself
• Cyriac Roeding, Earli
Fireside Chat: Immune Tolerance to Cure, A Conversation With...
• Lee Hood, Institute for Systems Biology
• Mary E. Brunkow, Institute for Systems Biology
ADCs in the Checkpoint Era: Who Benefits, What to Combine, What to Avoid
• Chair: Shreya Badhrinarayanan, Pfizer
• Gerold Meinhardt, Daiichi Sankyo
• Vadim Koshkin, UCSF
Strategic IP Management in Cell and Gene Therapy: Navigating Legal and Practical Challenges
• Janet Xiao, Morrison & Foerster LLP
Targeting the Tumor Microenvironment (TME) in Practice: Biomarkers & Combos
• Chair: Ira Mellman, Medici Therapeutics
• Dmitry Gabrilovich, AstraZeneca
• Jennifer Mataraza, Novartis
• Nathan Fowler, BostonGene
• Christine Moussion, Genentech
Future Breakthroughs in TME Reprogramming: New Modalities, Smarter Delivery & Overcoming Resistance
• David Kirn, ReIGNITE
Radiopharmaceutical Therapy: New Targets, Isotopes, and Challenges
• Chair: William Oh, Yale
• Munir Ghesani, United Theranostics
• Sandy Srinivas, Stanford
• Anna Karmann, AdvanCell
